Publications by authors named "Carlos Jimenez Chillon"
Survival after allogeneic transplantation according to pretransplant minimal residual disease and conditioning intensity in patients with acute myeloid leukemia.
Front Oncol
May 2024
Article Synopsis
- Pretransplant measurement of minimal residual disease (MRD) in acute myeloid leukemia (AML) patients undergoing hematopoietic stem cell transplantation (HSCT) impacts their prognosis, particularly in relation to conditioning intensity.
- * The study analyzed transplant outcomes of 118 AML patients, revealing that those with positive MRD (MRD+) before HSCT had significantly worse event-free survival (EFS) and higher relapse rates compared to those with negative MRD (MRD-).
- * Among patients treated with myeloablative conditioning (MAC), MRD- patients fared better in terms of EFS and overall survival, while those receiving reduced intensity conditioning (RIC) showed similar outcomes, regardless of MRD status.*
Molecular failure in NPM1-mutated acute myeloid leukemia (AML) inevitably progresses to frank relapse if untreated. Recently published small case series show that venetoclax combined with low-dose cytarabine or azacitidine can reduce or eliminate measurable residual disease (MRD). Here, we report on an international multicenter cohort of 79 patients treated for molecular failure with venetoclax combinations and report an overall molecular response (≥1-log reduction in MRD) in 66 patients (84%) and MRD negativity in 56 (71%).
View Article and Find Full Text PDFBackground: Despite recent advances, 40-85% of patients with acute myeloid leukaemia (AML) achieve complete remission after intensive chemotherapy. However, without optimal treatment after remission, the risk of relapse remains high.
Summary: A variable number of consolidation cycles consisting of intermediate doses of cytarabine are the most commonly used regimens in low-intermediate-risk AML, while patients at higher risk of relapse should consolidate response by proceeding to HSCT.
Patients with secondary acute myeloid leukemia undergoing allogeneic stem-cell transplant have inferior outcomes than de novo acute myeloid leukemia regardless minimal residual disease level by flow cytometry.
Hematol Oncol
October 2023
Article Synopsis
- Patients with secondary acute myeloid leukemia (s-AML) do not do as well after treatment compared to those with regular (de novo) acute myeloid leukemia (AML).
- A study compared 58 s-AML patients with 52 de novo AML patients who had a stem-cell transplant.
- The results showed that s-AML patients had a higher chance of health problems and dying after the transplant, especially if they weren’t in complete remission before the procedure.
Background: During the COVID-19 outbreak, most hospitals deferred elective surgical procedures to allow space for the overwhelming number of COVID-19 patient admissions, expecting a decrease in routine blood component requirements. However, because transfusion support needs of COVID-19 patients are not well known, its impact on hospital blood supply is uncertain. The objective of this study was to assess the effect of the COVID-19 pandemic on transfusion demand.
View Article and Find Full Text PDF